Corpus 1,277 assessed · 1,178 scored · 644 reproduced ≥75 · 170 flagged ·∅ 74/100

Publications 4 Datasets 392.5k Experiments 4.8k

Explore

Filters: CN ✕ 1 ✕ imaging ✕ clear all

4 matching publication(s)

Publication	Journal	Year	Score	Verdict
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). PMID 38897205	Cell Rep Med	2024	72	L1 72/100
PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells. PMID 37231145	NPJ Precis Oncol	2023	40	L1 40/100
GSDME-mediated pyroptosis promotes the progression and associated inflammation of atherosclerosis. PMID 36807553	Nat Commun	2023	85	85/100
Dynamics and regulation of mitotic chromatin accessibility bookmarking at single-cell resolution. PMID 36696508	Sci Adv	2023	50	L2 50/100

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

PMID 38897205 · Cell Rep Med · 2024

L1 72/100

PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells.

PMID 37231145 · NPJ Precis Oncol · 2023

L1 40/100

GSDME-mediated pyroptosis promotes the progression and associated inflammation of atherosclerosis.

PMID 36807553 · Nat Commun · 2023

85/100

Dynamics and regulation of mitotic chromatin accessibility bookmarking at single-cell resolution.

PMID 36696508 · Sci Adv · 2023

L2 50/100